ESTRO 2024 - Abstract Book

S2458

Clinical - Urology

ESTRO 2024

No significant toxicities related to SBRT were reported. A separate analysis of patients' reported outcomes on QoL is ongoing.

Conclusion:

The RADIOSA trial showed a significant improvement in terms of CP rate in the ADT + SBRT ARM suggesting a clinical advantage for the treatment combination for oligorecurrent hormone-sensitive PCa patients.

Considering that almost all ARM B patients achieved testosterone recovery at one year, these results support the safety and effectiveness of adding a short-course (6 months) ADT to SBRT. Longer FU data will provide clearer indication about the safety and effectiveness of such approach. Molecular analyses of biological samples collected within the trial are ongoing, and will hopefully help to identify a genomic signature to be integrated with next generation imaging allowing for a more refined oligometastatic patients stratification and treatment personalization.

Keywords: oligometastatic PCa, RADIOSA trial, ADT

References:

1. Marvaso, G., Ciardo, D., Corrao, G., Gandini, S., Fodor, C., Zerini, D., Rojas, D. P., Augugliaro, M., Bonizzi, G., Pece, S., Cattani, F., Mazzocco, K., Mistretta, F. A., Musi, G., Alessi, S., Petralia, G., Pravettoni, G., De Cobelli, O., Di Fiore, P. P., … Jereczek- Fossa, B. A. (2019). Radioablation +/− hormonotherapy for prostate cancer oligorecurrences (Radiosa trial): Potential of imaging and biology (AIRC IG-22159). BMC Cancer, 19(1), 903. https://doi.org/10.1186/s12885-019 6117-z